Galectin Therapeutics (NASDAQ:GALT) has announced the election of Dr. Marc Rubin as chairman, succeeding James Czirr, who helped found the company in 2000. Mr. Czirr will continue as a director.
Dr. Rubin is a leading bioscience industry executive with more than 25 years of senior management and board experience in the development and commercialization of pharmaceuticals. He has been serving as lead independent director of Galectin.
Dr. Rubin is currently executive chairman of the board of Titan Pharmaceuticals (NASDAQ:TTNP) and served as president and CEO from October 2007 to January 2009.
“As chairman, I look forward to playing a more active role in leading Galectin’s highly experienced board and working with its capable management team,” Dr. Rubin said in a statement.
Galectin is focusing initially on a unique approach to liver disease but with potential applicability to a vast array of diseases in which fibrosis plays a role.
“It is my belief that this is a company that is poised for exceptional accomplishments over the next few years,” he added.
